Immunovant to Present at the H.C. Wainwright Global Investment Conference on May 25th
May 23, 2022 16:05 ET
|
Immunovant
NEW YORK, May 23, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Present at the UBS Global Healthcare Conference on May 23rd
May 19, 2022 16:05 ET
|
Immunovant
NEW YORK, May 19, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Present at LifeSci Partners’ Immunology and Inflammation Symposium on May 10th
May 04, 2022 08:00 ET
|
Immunovant
NEW YORK, May 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Host Virtual R&D Day on March 30, 2022
March 28, 2022 07:00 ET
|
Immunovant
NEW YORK, March 28, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant to Present at the 11th Annual SVB Leerink Global Healthcare Conference
February 09, 2022 08:00 ET
|
Immunovant
NEW YORK, Feb. 09, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Reports Financial Results for the Quarter Ended December 31, 2021
February 04, 2022 07:00 ET
|
Immunovant
NEW YORK, Feb. 04, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Appoints Mark Levine as Chief Legal Officer
January 25, 2022 08:30 ET
|
Immunovant
Mr. Levine adds valuable experience to the leadership team as Immunovant accelerates the development of batoclimab with the expected initiation of three pivotal trials in 2022 NEW YORK, Jan. 25,...
Immunovant to Present at the 40th Annual J.P. Morgan Healthcare Conference
January 07, 2022 14:07 ET
|
Immunovant
NEW YORK, Jan. 07, 2022 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...
Immunovant Provides Regulatory Update Regarding Initiation of Phase 3 Trial for Batoclimab in Myasthenia Gravis in the First Half of 2022
December 30, 2021 07:00 ET
|
Immunovant
NEW YORK, Dec. 30, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases,...
Immunovant to Present at the Stifel 2021 Virtual Healthcare Conference
November 12, 2021 12:18 ET
|
Immunovant
NEW YORK, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage biopharmaceutical company focused on enabling normal lives for people with autoimmune diseases, today...